Esketamine for TRD: MOA, Application, and Adverse Events

Opinion
Video

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

Recent Videos
Geoffrey Grammer, MD, presenting slides
William Sauve, MD, presenting slides
Harman Deol, MD, presenting slides
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Casey Paleos, MD | Credit: LinkedIn
Related Content
Semaglutide Not Linked to Suicidal Risks in Those Without Major Psychiatric Disorders

Semaglutide Not Linked to Suicidal Risks in Those Without Major Psychiatric Disorders

Chelsie Derman
September 4th 2024
Article
The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

Kevin Kunzmann
January 11th 2024
Podcast
Phase 2 Data Supports the Effectiveness, Safety of NBI-1117568 for Schizophrenia

Phase 2 Data Supports the Effectiveness, Safety of NBI-1117568 for Schizophrenia

Chelsie Derman
August 28th 2024
Article
John J. Miller, MD: A New Era For Psychiatric Medications

John J. Miller, MD: A New Era For Psychiatric Medications

Kenny Walter
August 18th 2022
Podcast
Semaglutide Linked to Suicidal Ideation, New Study Reveals

Semaglutide Linked to Suicidal Ideation, New Study Reveals

Chelsie Derman
August 23rd 2024
Article
Unvaccinated People at Risk of Facing Mental Illness Up to a Year After COVID-19

Unvaccinated People at Risk of Facing Mental Illness Up to a Year After COVID-19

Chelsie Derman
August 22nd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.